SCHEMBL2298215

SCHEMBL2298215

CC(Cl)OC(=O)N1CCO[C@H](c2ccc(Br)cc2)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
ALOX12 P18054 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
POLB P06746 2/20 0.36
PDE4B Q07343 1/20 0.35
MAPT P10636 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
DRD2 P14416 1/20 0.34
DRD3 P35462 1/20 0.34
AKR1C3 P42330 1/20 0.34
CHRNA7 P36544 1/20 0.34
MGAT2 Q10469 1/20 0.34
MOGAT2 Q3SYC2 1/20 0.34
KRAS P01116 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2296411 1.00 USP30 (0.39) USP30L3MBTL1ALDH1A1KDM4EALOX12
SCHEMBL2297060 0.89 GRIN2B (0.40) USP30DRD3
SCHEMBL2298342 0.89 GRIN2B (0.40) USP30DRD3
SCHEMBL2294164 0.88 MOGAT2 (0.44) USP30DRD3MGAT2MOGAT2KMT2A
SCHEMBL2297679 0.88 MOGAT2 (0.44) USP30DRD3MGAT2MOGAT2KMT2A
SCHEMBL2299421 0.85 USP30 (0.41) USP30L3MBTL1ALDH1A1POLBPDE4B
SCHEMBL2294982 0.85 USP30 (0.41) USP30L3MBTL1ALDH1A1POLBPDE4B
SCHEMBL2295526 0.84 MAPT (0.45) USP30ALDH1A1KDM4EPOLBMAPT
SCHEMBL2293763 0.84 MAPT (0.45) USP30ALDH1A1KDM4EPOLBMAPT
SCHEMBL2297496 0.83 MOGAT2 (0.37) USP30L3MBTL1ALDH1A1PDE4BSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-20 US disclosed
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF SANOFI-AVENTIS (FR) 2011-10-13 US disclosed
US-7994315-B2 Intermediate compound for synthesizing pharmaceutical agent and production method thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257392-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 USP30 3057/4885L3MBTL1 4453/4885ALDH1A1 1251/4885
US-20110251385-A1 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MAPT, PSEN1, PSEN2 USP30 3057/4885L3MBTL1 4453/4885ALDH1A1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.